Chi-Med Files Application to List in Hong Kong and Announces Proposed Global Offering
15 avr. 2019 02h23 HE
|
Hutchison China MediTech Limited
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION HONG KONG,...
Chi-Med Initiates a Phase IIb/III Trial of Surufatinib in Patients with Unresectable or Metastatic Biliary Tract Cancer in China
29 mars 2019 03h00 HE
|
Hutchison China MediTech Limited
LONDON, March 29, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has initiated a registration-enabling Phase IIb/III study comparing surufatinib (HMPL-012 or...
Chi-Med Highlights Oral Presentations on Savolitinib Lung Cancer Programs at AACR Annual Meeting
28 mars 2019 03h30 HE
|
Hutchison China MediTech Limited
LONDON, March 28, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will share further data on the savolitinib development programs in lung cancer at the...
Chi-Med Reports 2018 Full Year Results and Provides Updates on Key Clinical Programs
11 mars 2019 02h00 HE
|
Hutchison China MediTech Limited
LONDON, March 11, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces its audited financial results for the year ended December 31, 2018 and...
Chi-Med Highlights Preliminary Phase II Savolitinib / Imfinzi® Combination Data in Advanced Papillary Renal Cell Carcinoma at 2019 ASCO Genitourinary Cancers Symposium
12 févr. 2019 02h18 HE
|
Hutchison China MediTech Limited
LONDON, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announced the availability of preliminary results from the Phase II CALYPSO study of...
Chi-Med to Announce 2018 Final Results
08 févr. 2019 02h34 HE
|
Hutchison China MediTech Limited
LONDON, Feb. 08, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) will announce its final results for the year ended December 31, 2018 on Monday, March 11,...
Chi-Med to Present at the 37th Annual JP Morgan Healthcare Conference
07 janv. 2019 02h00 HE
|
Hutchison China MediTech Limited
LONDON, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces that Christian Hogg, Chief Executive Officer, will present at the 37th Annual...
Chi-Med Announces Progress in Savolitinib Lung Cancer Program and Update on Kidney Cancer Strategy
20 déc. 2018 02h28 HE
|
Hutchison China MediTech Limited
– Global SAVANNAH study of savolitinib / Tagrisso® combination in MET+ EGFRm NSCLC underway. Data presented at ESMO 2018 showed MET-amplification among themost frequent mechanisms of acquired...
Chi-Med Announces Amendment to the 2013 License & Collaboration Agreement on Fruquintinib with Eli Lilly and Company
20 déc. 2018 02h00 HE
|
Hutchison China MediTech Limited
– Chi-Med acquires right to determine & conduct all future life cycle indication development of fruquintinib monotherapy as well as innovative combinations in China – – Chi-Med to assume all...
Chi-Med Enters into Multiple Collaborations to Evaluate Combinations of Surufatinib and Fruquintinib with PD-1 Checkpoint Inhibitors
29 nov. 2018 03h00 HE
|
Hutchison China MediTech Limited
LONDON, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) entered into four collaboration agreements to evaluate the safety, tolerability and efficacy...